WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017188720) QUINAZOLINE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/188720 International Application No.: PCT/KR2017/004424
Publication Date: 02.11.2017 International Filing Date: 26.04.2017
IPC:
C07D 239/72 (2006.01) ,C07D 403/04 (2006.01) ,A61K 31/517 (2006.01) ,A61K 31/506 (2006.01)
Applicants: YUHAN CORPORATION[KR/KR]; 74, Noryangjin-ro Dongjak-gu Seoul 06927, KR
Inventors: KIM, Young-Hwan; KR
HAN, Tae-Dong; KR
KIM, Dong-Hoon; KR
JUNG, Eun-Hye; KR
CHOI, Su-Bin; KR
LEE, Eui-Chul; KR
CHONG, Won-Ee; KR
PARK, Jin-Hwi; KR
PARK, Jun-Chul; KR
KANG, Ho-Woong; KR
GAL, Ji-Yeong; KR
PARK, Chan-Sun; KR
KIM, Jong-Gyun; KR
NAM, Su-Youn; KR
Agent: OH, Kook-Jin; KR
Priority Data:
10-2016-005303329.04.2016KR
Title (EN) QUINAZOLINE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
(FR) DÉRIVÉ DE QUINAZOLINE OU SON SEL ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
Abstract: front page image
(EN) The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.
(FR) La présente invention concerne un dérivé de quinazoline ou son sel pharmaceutiquement acceptable, son procédé de préparation, une composition pharmaceutique le comprenant, et son utilisation. Le dérivé de quinazoline ou son sel pharmaceutiquement acceptable a une activité inhibitrice sélective contre la sous-unité delta de la phosphatidylinositol 3-kinase, et par conséquent peut être utilement appliqué pour prévenir ou traiter le cancer, ainsi que pour éviter les effets secondaires tels que les réponses inflammatoires associées à la lymphopénie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)